Author and co-author of 47 articles in international journals with IF; 584 citations (WoS; excluding self-citations); H-index: 15 (WoS).
-
Reimerová P., Stariat J., Bavlovič Piskáčková H., Jansová H., Roh J., Kalinowski D.S., Macháček M., Šimůnek T., Richardson D.R., Štěrbová-Kovaříková P. Novel SPME fibers based on a plastic support for determination of plasma protein binding of thiosemicarbazone metal chelators: a case example of DpC, an anti-cancer drug that entered clinical trials. Analytical and Bioanalytical Chemistry. 2019;. doi: 10.1007/s00216-019-01681-w. (IF2017=3.307)
-
Reimerová P., Jirkovská A., Bavlovic Piskackova H., Karabanovich G., Roh J., Šimůnek T., Štěrbová-Kovaříková P. UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study. Scientific Reports. 2019; 9(1):4524 (IF2017=4.122)
-
Jansová H., Kubeš J., Reimerová P., Štěrbová-Kovaříková P., Roh J., Šimůnek T. 2,6-Dihydroxybenzaldehyde Analogues of the Iron Chelator Salicylaldehyde Isonicotinoyl Hydrazone: Increased Hydrolytic Stability and Cytoprotective Activity against Oxidative Stress. Chemical Research in Toxicology. 2018; 31(11):1151-1163. (IF2017=3.432)
-
Hrušková K,. Potůčková E., Opálka L., Hergeselová T., Hašková P., Kovaříková P., Šimůnek T., Vávrová K. Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities. Chemical Research in Toxicology. 2018;31(6):435-446 (IF2017=3.432)
-
Jirkovský E., Jirkovská A., Bureš J., Chládek J., Lenčová O., Stariat J., Pokorná Z., Karabanovich G., Roh J., Brázdová P., Šimůnek T., Kovaříková P., Štěrba M. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. Journal of Pharmacology and Experimental Therapeutics. 2018;364:433-446. (IF2017= 3.706)
-
Bures J., Jirkovska A., Sestak V., Jansova H., Karabanovich G., Roh J., Sterba M., Simunek T., Kovarikova P. Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite. Toxicology. 2017;392:1-10. (IF2017=3.265)
-
Sestak V., Roh J., Klepalova L., Kovarikova P. A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor, Journal of Pharmaceutical and Biomedical Analysis. 2016; 124: 365-73 (IF2016=3.255)
-
Jansová H., Bureš J., Macháček M., Hašková P., Jirkovská A., Roh J., Wang Q., Franz K.J., Kovaříková P., Šimůnek T. Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products, Toxicology. 2016; 350-352:15-24 (IF2016=3.582)
-
Hrušková K., Potůčková E., Hergeselová T., Liptáková L., Hašková P., Mingas P., Kovaříková P., Šimůnek T., Vávrová K. Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications, European Journal of Medicinal Chemistry. 2016; 120:97-110 (IF2016=4.519)
-
Tycova A., Vido M., Kovarikova P., Foret F. Interface-free capillary electrophoresis-mass spectrometry system with nanospray ionization-Analysis of dexrazoxane in blood plasma, Journal of Chromatography A. 2016; 1466:173-9. (IF2016=3.891)
-
Lenčová-Popelová O., Jansová H., Jirkovský E., Bureš J., Jirkovská-Vávrová A., Mazurová Y., Reimerová P., Vostatková L., Adamcová M., Hroch M., Pokorná Z., Kovaříková P., Šimůnek T, Štěrba M. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Toxicology. 2016; 372:52-63. (IF2016=3.582)
-
Hašková P., Jansová H., Bureš J., Macháček M., Jirkovská A., Franz K.J., Kovaříková P., Šimůnek T.Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. Toxicology. 2016; 371:17-28. (IF2016=3.582)
-
Šesták V., Stariat J., Cermanová J., Potůčková E., Chládek J., Roh J., Bureš J., Jansová H., Průša P., Stěrba M., Mičuda S., Šimůnek T., Kalinowski D. S., Richardson D.R., Kovaříková P. Novel and Potent Anti-Tumor and Anti-Metastatic Di-2-Pyridylketone Thiosemicarbazones Demonstrate Marked Differences in Pharmacology Between the First and Second Generation Lead Agents, Oncotarget. 2015; 6(40):42411-28 (IF2015=5.008)
-
Potůčková E., Roh J., Macháček M., Sahni S., Stariat J., Šesták V., Jansová H., Hašková P., Jirkovská A., Vávrová K., Kovaříková P., Kalinowski D. S., Richardson D. R., Šimůnek T. In vitro characterization of the pharmacological properties of the anti-cancer chelator, Bp4eT, and ts phase I metabolites, PLoS ONE. 2015; 10(10): e0139929 (IF2015=3.057)
-
Bureš J., Jansová H., Stariat J., Filipský T., Mladěnka P., Šimůnek T., Kučera R., Klimeš J., Wang Q., Franz K.J., Kovaříková P. LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). Journal of Pharmaceutical and Biomedical Analysis. 2015; 105(1): 55-63. (IF2015= 3.169)
-
Potůčková E., Hrušková K., Bureš J., Kovaříková P., Špirková I.A., Pravdíková K., Kolbabová L., Hergeselová T., Hašková .P, Jansová H, Macháček M., Jirkovská A., Richardson V., Lane D.J., Kalinowski D.S., Richardson D.R., Vávrová K., Šimůnek T. Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties. PLoS One. 2014, 9(11): e112059. (IF2014= 3.232)
-
Cermanova J., Kadova Z., Dolezelova E., Zagorova M., Safka V., Hroch M., Laho T., Holeckova M., Mokry J., Kovarikova P., Bures J., Sterba M., Micuda S. Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats. Shock. 2014, 42(4):372-79. (IF2014= 3.045)
-
Kučera R., Kovaříková P., Pasáková-Vrbatová .I, Slaninová J., Klimeš J. Zirconia--a stationary phase capable of the separation of polar markers of myocardial metabolism in hydrophilic interaction chromatography. Journal of Separation Science. 2014, 37(9-10):1089-93. (IF2013= 2.594)
-
Stariat J., Suprunová V., Roh J., Šesták V., Eisner T., Filipský T., Mladěnka P., Nobilis M., Šimůnek T., Klimeš J., Kalinowski D.S., Richardson D.R., Kovaříková P. Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: Application to a pilot pharmacokinetic study in rats. Biomedical Chromatography. 2014; 28(5):621-9 (IF2013= 1.662)
-
Stariat J., Kovaříková P., Kučera R., Klimeš J., Kalinowski D.S, Richardson D.R, Ketola R.A. Identification of in vitro metabolites of the novel anti-tumor thiosemicarbazone, DpC, using ultra-high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry, Analytical and Bioanalytical Chemistry. 2013; 405(5):1651-61. (IF2013= 3.578)
-
Kovaříková P., Pasaková-Vrbatová I., Vávrová A., Stariat J., Klimeš J., Simunek T. Development of LC–MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium, Journal of Pharmaceutical and Biomedical Analysis .2013; 76(1): 243-51. (IF2013= 2.829)
-
Štěrba M., Popelová O., Vávrová A., Jirkovský E., Kovaříková P., Geršl V., Šimůnek T. Oxidative stress, redox signaling and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection, Antioxidants & Redox Signaling. 2013; 18(8): 899-929. (IF2013: 7.667)
-
Macková E., Hrušková K., Bendová P., Vávrová A., Jansová H., Hašková P., Kovaříková P., Vávrová K., Šimůnek T. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: Novel iron chelators with selective antiproliferative action. Chemico-Biological Interactions. 2012; 197: 69-79. (IF2011: 2.865)
-
Stariat J., Šesták V., Vávrová K., Nobilis M., Kollárová Z., Klimeš J., Kalinowski D.S., Richardson D.R., Kovaříková P. LC-MS/MS identification of the principal in vitro and in vivo phase I metabolites of the novel thiosemicarbazone anti-cancer drug, Bp4eT, Analytical and Bioanalytical Chemistry. 2012; 403(1): 309-321. (IF2011: 3.778)
-
Vávrová K., Kovaříková P., Školová B., Líbalová M., Roh J., Čáp R., Holý A., Hrabálek A. Enhanced Topical and Transdermal Delivery of Antineoplastic and Antiviral Acyclic Nucleoside Phosphonate cPr-PMEDAP. Pharmaceutical Research. 2011; 28(12): 3105-3115. (IF2010: 4.456)
-
Hašková P., Koubková L., Vávrová A., Macková E., Hrušková K., Kovaříková P., Vávrová K., Šimůnek T. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity. Toxicology. 2011; 28(2-3): 122-131. (IF2011: 3.681)
-
Kučera R., Kovaříková P., Klivický M., Klimeš J. The retention behaviour of polar compounds on zirconia based stationary phases under hydrophilic interaction liquid chromatography conditions, Journal of Chromatography A. 2011; 1218(39): 6981-6986. (IF2011: 4.531)
-
Pasáková I., Gladziszová M., Charvátová J., Stariat J., Klimeš J., Kovaříková P. Use of different stationary phases for separation of isoniazid, its metabolites and vitamin B6 forms, Journal of Separation Science. 2011; 34(12): 1357-1365. (IF2011: 2.733)
-
Hrušková K., Kovaříková P., Bendová P., Hašková P., Macková E., Stariat J., Vávrová A., Vávrová K., Šimůnek T. Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis, Chemical Research in Toxicology. 2011; 24(3): 290-302. (IF2011: 3.779)
-
Hašková P., Kovaříková P., Koubková L., Vávrová A., Macková E., Šimůnek T. Iron chelation with salicylaldehyde isonicotinoyl hydrazone (SIH) protects against catecholamine autooxidation and cardiotoxicity, Free Radical Biology and Medicine. 2011; 50(4): 537-549. (IF2011: 5.423)
-
Kovaříková P., Stariat J., Klimeš J., Hrušková K., Vávrová K. Hydrophilic interaction liquid chromatography in the separation of a moderately lipophilic drug from its highly polar metabolites - The cardioprotectant dexrazoxane as a model case, Journal of Chromatography A. 2011; 1218(3): 416-426. (IF2011: 4.531)
-
Bendová P., Macková E., Hašková P., Vávrová A., Jirkovský E., Šterba M., Popelová O., Kalinowski D.S, Kovaříková P., Vávrová K., Richardson D.R, Šimůnek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury, Chemical Research in Toxicology. 2010; 23(6): 1105-1114. (IF2010: 4.140)
-
Stariat J., Kovaříková P., Klimeš J., Kalinowski D.S., Richardson D.R. Development of an LC-MS/MS method for analysis of interconvertible Z/E Isomers of novel anti-cancer agent, Bp4eT, Analytical and Bioanalytical Chemistry. 2010; 397(1): 161-171. (IF2010: 3.841)
-
Pasáková I., Kovaříková P., Kučera R., Klimeš J., Sochor J., Hrabálek A. Development and validation of an LC-ESI-MS ion-trap method for analysis of impurities in Transkarbam 12, a novel transdermal accelerant Chromatographia. 2009; 96(9-10): 977-983. (IF2009: 1.098)
-
Novotný J., Kovaříková P., Novotný M., Janušová B., Hrabálek A., Vávrová K. Dimethylamino acid esters as biodegradable and reversible transdermal permeation enhancers: Effects of linking chain length, chirality and polyfluorination, Pharmaceutical Research. 2009; 26(4): 811 – 821. (IF2009: 3.933)
-
Stariat J., Kovaříková P., Klimeš J., Lovejoy D.B., Kalinowski D.S., Richardson D.R. HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents, Journal of Chromatography B. 2009; 877(3): 316 – 322. (IF2009: 2.777)